Apellis to Showcase VALIANT Study Insights at ASN Kidney Week
Apellis Pharmaceuticals Announces VALIANT Study Presentation Details
WALTHAM, Mass. — Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) has shared exciting news about their Phase 3 VALIANT study of pegcetacoplan, a potential treatment for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study's abstract will be presented at the prestigious American Society of Nephrology (ASN) Kidney Week, held from October 23 to 27.
Webinar Announcement
Following this significant presentation, Apellis will host a webinar to dive deeper into the VALIANT results. The live session is scheduled for October 26 at 12:30 p.m. PT, making it a prime opportunity for healthcare professionals and stakeholders to engage with the findings directly from the company’s leading experts.
High Impact Clinical Trials Oral Presentation Details
The presentation highlights the rigorous work underlying the VALIANT study. Dr. Carla Nester, M.D., MSA, FASN, is set to lead this oral presentation titled:
“VALIANT: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Trial of Pegcetacoplan for Patients with Native or Post-transplant Recurrent Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN).” This session is slated for Saturday, October 26, at 11:00 a.m. PT in Hall D of the convention center.
Additional Poster Presentations
In addition to the oral presentation, Apellis has two abstracts accepted for poster presentations during Kidney Week. These posters will showcase:
“Pegcetacoplan for Post-transplant Recurrent C3 Glomerulopathy (C3G) or Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) in NOBLE: 52-Week Patient Evolution” by Dr. Anuja Java, M.D. and “Long-Term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis: The Long-Term VALE Extension Study” by Dr. Carla Nester, M.D., MSA, FASN. Both of these presentations are scheduled for Saturday, October 26, at 10:00 a.m. PT in the exhibition hall.
In-Depth on the VALIANT Study
The VALIANT Phase 3 study evaluates pegcetacoplan's efficacy and safety for C3G and IC-MPGN. It stands as the largest single trial conducted for these patient populations, analyzing data from 124 individuals aged 12 and older. Participants received either pegcetacoplan or a placebo twice weekly over a 26-week timeframe, after which they transitioned into an open-label phase receiving the treatment. The primary endpoint focuses on the urine protein-to-creatinine ratio to assess treatment efficacy.
Understanding C3 Glomerulopathy and IC-MPGN
C3G and IC-MPGN are complex kidney disorders often leading to kidney failure, with a survival rate post-diagnosis revealing that around half of patients may experience kidney failure within five to ten years. The recurrence rate in individuals post-transplant is significantly high, which stresses the urgent need for effective treatments targeting the underlying causes.
Pegcetacoplan's Role in Rare Kidney Diseases
Pegcetacoplan operates as a targeted therapy that aims to control the over-activation of the complement cascade, which is linked to various serious conditions. Notably, this medication is also approved for treating paroxysmal nocturnal hemoglobinuria (PNH) as EMPAVELI/Aspaveli in numerous regions, thus highlighting its broader therapeutic impact in rare disease management.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. is dedicated to blending innovative science with empathetic care in the development of transformative therapies. With two approved treatments targeting C3, including a groundbreaking option for geographic atrophy, Apellis is poised to expand its frontiers in addressing serious conditions across multiple medical landscapes.
For media inquiries, reach out to:
Media Contact:
Tracy Vineis
media@apellis.com
617.420.4839
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
Frequently Asked Questions
What is the VALIANT study about?
The VALIANT study investigates the efficacy and safety of pegcetacoplan for treating C3 glomerulopathy and IC-MPGN.
When will the VALIANT study results be presented?
The results will be presented at the ASN Kidney Week on October 26 at 11:00 a.m. PT.
How can I participate in the webinar?
The webinar discussing the VALIANT study results is scheduled for October 26 at 12:30 p.m. PT.
What are C3G and IC-MPGN?
C3G and IC-MPGN are rare kidney diseases that can lead to kidney failure and currently have no targeted therapies.
What role does pegcetacoplan play in treating these conditions?
Pegcetacoplan targets the complement system, which is believed to play a role in the progression of C3G and IC-MPGN, providing a potentially effective treatment option.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Neutrinos Launches Intelligent Automation Solution for Insurers
- Wendel Strengthens Educational Presence with Globeducate Stake
- HighCo Reports Slightly Improved Q3 2024 Gross Profit Insights
- ObvioHealth Appoints Richard Watkins as New Chief Revenue Officer
- MDB Capital and TCA Venture Group Join Forces to Empower Investors
- Boussard & Gavaudan Holding Limited Updates Final NAV Figures
- Boussard & Gavaudan Holding Limited Reports Final NAV Update
- Discover the Culinary World with Eater's New App Launch
- Evaluating Changes in HR Executive Compensation Trends
- Understanding Investor Sentiment for United Rentals Stock
Recent Articles
- Discovering Top-Rated Stocks: First Solar and Clearway Energy
- Orally Disintegrating Tablets Set for Remarkable Growth Ahead
- Qualcomm's Strategic Decision: Waiting for Post-Election Insights
- Hydreight Technologies Reports Impressive Growth and Revenue Surge
- Introducing ECOTRIA CLARO 300: A New Era in Sustainable Packaging
- Green Ammo Secures Vital Defense Contracts Amid Shortages
- Perspective Therapeutics Enhances Production Capabilities
- Main Street Capital Solidifies Position with New $41.4 Million Deal
- Scilex Holding Explores Strategies for Enhancing Subsidiary Value
- Gyrodyne Celebrates Legal Victory for Flowerfield Development
- B. Riley Financial Announces Cash Dividends for Preferred Stock
- Apellis Presents Findings on Pegcetacoplan at ASN Kidney Week
- EyePoint Pharmaceuticals Expands Staff with Inducement Grants
- Criteo Set to Reveal Third Quarter Financial Insights
- Innovative Biotech Company Apogee Therapeutics to Showcase New Data
- CLN-978's FDA Clearance Marks a New Era for Autoimmune Treatment
- Square Honors Canadian Businesses Among Global Leaders
- Ardagh Metal Packaging's Strategic Move into Renewable Energy
- Invivyd Showcases PEMGARDA™ Advances at IDWeek 2024
- Freightos Achieves Milestones in Q3 with Outstanding Growth
- CI Global Asset Management Highlights October 2024 ETF Distributions
- Invivyd Set to Showcase PEMGARDA™ Findings at Upcoming Event
- Enthusiast Gaming's Smash Bros Event Draws Record Online Viewers
- Harris Poll Launches Canada Ranking of Corporate Reputation
- STP Investment Services Expands Offerings with ComplianceAdvisor
- Canadian Government Announces Major Housing Initiative
- Luxury Villas Set to Transform Palm Jebel Ali Landscape
- Pivotree's Strategic Changes and Future Focus Unveiled
- Akeso Reports Promising Outcomes from Cadonilimab Study
- Discover the 2024 SCALEit® Accelerator for Business Growth
- AlphaGraphics Welcomes Don Carpenter as Senior Franchise Director
- Enerpac Earnings Report: Navigating Challenges for FY25
- Rothy's Offers $10,000 to Encourage Car-Free Living for a Month
- How Financial Support from Grandparents Shapes Futures
- Barrick Gold's Q3 2024 Production Highlights and Future Prospects
- Eliassen Group Strengthens Market Position with VIA Technical Deal
- Mesa Air Group's Q3 2024 Recap: Financial Highlights and Outlook
- Unlocking Competitive Advantages Through AI in eCommerce
- 1-800-Packouts Launches Hurricane Relief Fund for Recovery
- Investor Optimism in Europe Hits New Heights Amid Shift
- New Members Enhancing Ethical AI Council Led by Visionaries
- Exploring the Benefits and Future of Tankless Water Heaters
- Yum! Brands Faces New Challenges as Analysts Adjust Outlook
- LVMH Navigates Cautious Luxury Market with Strong Fundamentals
- Empowering Seniors: A New Chapter for Caring Senior Service
- Wolters Kluwer Launches Innovative User Conference in Vegas
- L'Oreal's Stock Forecast Challenges Amid Market Dynamics
- Cyngn Achieves Milestone with 21st U.S. Patent in AV Technology
- Revolutionizing Banking with Amount's Innovative Platform
- Instacart Faces Mixed Ratings Amid Market Challenges